+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Valneva SE (VLA) - Financial and Strategic SWOT Analysis Review

  • ID: 4282139
  • SWOT Analysis
  • 55 pages
  • GlobalData
  • Valneva SE
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

FEATURED COMPANIES

  • bioMerieux SA
  • Globeimmune Inc
  • Gotovax AB
  • Innate Pharma SA
  • Takeda Canada Inc
  • Themis Bioscience GmbH
  • MORE
Valneva SE (VLA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

Critical Information Included
  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities – A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Valneva SE (Valneva) is a biotechnology company that develops lifesaving vaccines against infectious diseases and cancer. The company's products include a vaccine indicated for the prevention of Japanese encephalitis; and a vaccine indicated for the prevention of cholera and diarrhea. Its pipeline encompasses investigational candidates for the prevention of lyme, chikungunya, and zika viral infectious. The company works in partnership with various pharmaceutical and biopharmaceutical companies to advance its pipeline vaccine candidates and to distribute its products. The company sells its products in the Americas, Asia Pacific, Europe and the Middle East. It operates in Austria, Sweden, the UK, France, Canada, and the US. Valneva is headquartered in Saint-Herblain, France.

Valneva SE Key Recent Developments

Jan 16, 2019 VALNEVA Confirms FY 2018 Guidance and Provides Initial Product Sales Revenue Guidance for 2019
Jan 07, 2019 VALNEVA announces its intention to delist from the vienna stock exchange
Nov 08, 2018 VALNEVA reports nine month results for 2018, confirms guidance, strengthens balance sheet with €50m financing
Oct 16, 2018 VALNEVA Announces Progress of Chikungunya Vaccine Candidate

Key Benefits

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • bioMerieux SA
  • Globeimmune Inc
  • Gotovax AB
  • Innate Pharma SA
  • Takeda Canada Inc
  • Themis Bioscience GmbH
  • MORE
Section 1 - About the Company
  • Valneva SE - Key Facts
  • Valneva SE - Key Employees
  • Valneva SE - Key Employee Biographies
  • Valneva SE - Major Products and Services
  • Valneva SE - History
  • Valneva SE - Company Statement
  • Valneva SE - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 – Company Analysis
  • Company Overview
  • Valneva SE - Business Description
  • Product Category: Dukoral
  • Overview
  • Performance
  • Product Category: Ixiaro/Jespect
  • Overview
  • Performance
  • Key Stats
  • Product Category: Revenues from Collaborations, Licensing and Services
  • Performance
  • R&D Overview
  • Valneva SE - Corporate Strategy
  • Valneva SE - SWOT Analysis
  • SWOT Analysis - Overview
  • Valneva SE - Strengths
  • Valneva SE - Weaknesses
  • Valneva SE - Opportunities
  • Valneva SE - Threats
  • Valneva SE - Key Competitors
Section 3 – Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
  • Valneva SE, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
  • Valneva SE, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
  • Valneva SE, Recent Deals Summary
Section 5 – Company’s Recent Developments
  • Jan 16, 2019: VALNEVA Confirms FY 2018 Guidance and Provides Initial Product Sales Revenue Guidance for 2019
  • Jan 07, 2019: VALNEVA announces its intention to delist from the vienna stock exchange
  • Nov 08, 2018: VALNEVA reports nine month results for 2018, confirms guidance, strengthens balance sheet with €50m financing
  • Oct 16, 2018: VALNEVA Announces Progress of Chikungunya Vaccine Candidate
  • Oct 05, 2018: VALNEVA Announces FDA Approval of Accelerated IXIARO® Vaccination Schedule
  • Sep 20, 2018: Valneva announces extension of drawdown period for its existing european investment bank loan
  • Aug 02, 2018: VALNEVA Delivers Strong IXIARO Sales Growth and reports Further Progress on Key R&D Programs in H1
  • Jun 29, 2018: VALNEVA Announces Successful Outcome of its AGM and Renewal of the Term of Office of its Management Board Members
  • Jun 13, 2018: Valneva: Protecting unborn babies from Zika
Section 6 – Appendix
  • Methodology
  • Ratio Definitions
  • About
  • Disclaimer
List of Tables
  • Valneva SE, Key Facts
  • Valneva SE, Key Employees
  • Valneva SE, Key Employee Biographies
  • Valneva SE, Major Products and Services
  • Valneva SE, History
  • Valneva SE, Other Locations
  • Valneva SE, Subsidiaries
  • Valneva SE, Key Competitors
  • Valneva SE, Ratios based on current share price
  • Valneva SE, Annual Ratios
  • Valneva SE, Interim Ratios
  • Valneva SE, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
  • Valneva SE, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
  • Valneva SE, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Valneva SE, Performance Chart (2013 - 2017)
  • Valneva SE, Ratio Charts
  • Valneva SE, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
  • Valneva SE, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Transgene SA
  • Themis Bioscience GmbH
  • Takeda Canada Inc
  • Innate Pharma SA
  • Gotovax AB
  • Globeimmune Inc
  • bioMerieux SA
Note: Product cover images may vary from those shown
Adroll
adroll